Abstract
Context: Elderlies are more prone to neurodegenerative diseases. One of the most common neurodegenerative diseases with limited effective treatments available is Alzheimer’s disease (AD). Adipose-derived stem cells (ADSCs) with neuroregenerative and neuroprotective capabilities have shown great potential to serve as a potential cellular therapy for AD. Adipose-derived stem cells’ efficacy in the treatment of AD is evaluated in this systematic review. Data Sources: Literature search was performed via PubMed, Cochrane Library, ScienceDirect, Wiley Online Library, and EBSCOhost databases, selecting studies which evaluated the effect of ADSCs on AD from inception to 6 August 2020. The SYRCLE Risk of Bias tool was used to assess pre-clinical studies in animal models, and MINORS Risk of Bias tool was used to assess non-randomized phase 1 clinical trials. Conclusions: Overall, seven studies, including two in-vitro studies, four in-vivo mice model studies, and one non-randomized phase 1 clinical trial, were included in this systematic review. Adipose-derived stem cells showed significant potential, proven by their neuroregenerative (i.e., increased neurogenesis, synaptogenesis, synaptic and dendritic stability, and cognitive and spatial skills) and neuroprotective capabilities (i..e., decreased Aβ concentration, APP-CT concentration, P-tau concentration, number of amyloid plaques, oxidative stress, and neuron apoptosis when exposed to Aβ). Adipose-derived stem cells demonstrated promising efficacy in treating AD patients.